Assurea serves as the IT/Computer System Validation unit for fast growing clients.

A biotech company may already have the data it needs to answer an important question. The problem is that the answer may be spread across five different systems. Consider one batch. The MES knows what happened during execution. The historian captures process conditions. LIMS contains laboratory results. The eQMS holds deviations and investigations. ERP contains

We’re excited to announce a new partnership between Assurea and Seeq to help pharma and biotech organizations adopt Seeq for Pharma within GxP-regulated environments. Assurea will serve as the implementation and validation partner for Seeq. As part of the partnership, Assurea has developed a validation package for Seeq that combines Assurea’s expertise in CSV and

In pharma and biotech, digital systems rarely stay the same after they go live. Workflows change, users increase, integrations are added, suppliers release updates, and the system becomes part of a larger operational environment. The real challenge is that oversight does not always evolve at the same pace. A system may still be validated, documented,

27 periodic reviews. 650+ documents analyzed. One clear view of system health. Periodic reviews are intended to answer a relatively simple question: is this GxP system or piece of computerized equipment still operating in a controlled and appropriately validated or qualified state? Getting to that answer is rarely simple. A reviewer may need to look

We’re excited to announce a new partnership between Assurea and Runtime Verification! As software becomes increasingly critical to medical devices, SaMD, and artificial organs, companies need stronger ways to demonstrate that their software is safe, reliable, and ready for use in a regulated environment. This partnership brings together two complementary strengths. Runtime Verification brings deep

SaaS and cloud validation is different because the regulated company no longer controls the full technical stack, but it still owns intended use, oversight, data integrity, access, and compliance. That is where many teams misunderstand the real validation challenge. When a system is vendor-hosted, the validation work does not go away. It shifts. Instead of

Auditing IT infrastructure in a GxP environment means checking whether the technical foundation behind regulated systems is controlled, supportable, and appropriate for its intended use. The audit should not stop at servers or network diagrams. It should test whether access, changes, backups, monitoring, and supporting services are managed in a way that protects system reliability

Pharma companies cannot rely on standard commercial SaaS contracts alone when regulated systems, GxP data, or AI-enabled workflows are involved. In regulated environments, contracts and SLAs help define operational oversight expectations that support validation, data integrity, cybersecurity, supplier governance, and inspection readiness. Most commercial agreements are designed around uptime and commercial liability. Pharma and biotech

For a growing biotech company, implementing the first major digital system is an important milestone. Paper records, spreadsheets, shared drives, and disconnected tools that worked during early growth may no longer support increasing operational complexity, regulatory expectations, or future scale. The natural response is often to start evaluating software. But selecting an eQMS, LIMS, LMS,

How AI-powered document analytics helps manufacturing teams compare complex documentation, identify process differences, and accelerate technology transfer while keeping GMP decisions under human oversight. Technology Transfer Is Still a Documentation-Intensive Process Successful technology transfer is about far more than moving a manufacturing process from one facility to another. It requires ensuring that manufacturing knowledge is

How Assurea validated a U.S. deployment of Veeva Vault Quality and established a reusable validation framework for future global site rollouts. Project Overview When a global Contract Development and Manufacturing Organization (CDMO) selected Veeva Vault Quality to standardize its quality management processes, the first deployment was planned for a U.S. manufacturing site located on the

How Assurea helped a biotechnology company assess and align site vs global QMS following an acquisition using AI-assisted analytics and expert quality review. Project Overview Following the acquisition of a biotechnology company, our client needed to understand how the acquired site’s Quality Management System (QMS) aligned with its global quality framework before beginning integration activities.

Many life sciences organizations commonly ask this question when implementing a SaaS platform: “If the vendor already validated the system, what do we still need to do?” The answer is straightforward. The vendor is responsible for the platform it develops, operates, and maintains. The regulated company remains responsible for how that platform is configured, governed,

Defining intended use is one of the most important steps in validating AI and SaaS tools in regulated pharma and biotech environments. The intended use statement establishes validation scope, testing strategy, risk classification, supplier oversight expectations, and procedural controls. For AI systems, this is often more difficult than traditional software because operational usage can evolve

An AI governance framework for pharma works only when it goes beyond policy. It needs to connect each AI use case to a clear intended use, a defined risk tier, required controls, and ongoing monitoring. That is what makes the framework usable in practice and defensible in audit. If those links are missing, the framework

In today’s digital biotech environment, labs and manufacturing sites rely on a complex network of interconnected systems: LIMS, QMS, MES, ERP, CDS, eBMRs, data historians, and analytics platforms. While each system may be validated independently, the movement of data between them is where the highest risk now lives. Regulators increasingly expect organizations to demonstrate end-to-end

Background: A Late-Stage Biopharma Preparing for EU Commercialization A mid-sized U.S.-based biopharmaceutical company was preparing to commercialize its first biologic product in the European Union. As part of its global expansion strategy, the company initiated a technology transfer from its U.S. clinical manufacturing facility to a commercial EU site (located in Ireland). While the company

Turning Supplier Audit Files into Actionable Insights for a Mid-Size Biotech Introduction A mid-size biotech organization with approximately 600 employees and a single GMP manufacturing site faced a common challenge: hundreds of supplier audit reports, self-assessment questionnaires, and CAPA summaries stored across multiple folders, but no easy way to extract trends or prioritize risks. The

Client: A Biotech CompanyIndustry: Life Sciences / Pharmaceutical ManufacturingSize: 150–200 employeesEngagement Type: Full-service contract staffing partnershipPartner: Assurea Background A rapidly growing biotech company specializing in cell and gene therapy recently secured Series C funding to expand its manufacturing capacity. The organization planned to establish a new biomanufacturing site in New Jersey, aimed at scaling production

The FDA has finalized its Computer Software Assurance for Production and Quality System Software guidance — a long-awaited update that signals the end of “business as usual” for software validation in regulated industries. For decades, Computerized System Validation (CSV) has been the framework life sciences companies relied on. While it provided structure, CSV often created